ICU Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Chartmill - Mentions: URBN WOOF HPQ INV ...

Get insights into the top gainers and losers of Tuesday's after-hours session.

5 days ago - By: SeaStar Medical

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

17 days ago - By: SeaStar Medical

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

20 days ago - By: SeaStar Medical

SeaStar Medical Announces Appointment of Michael Messinger as CFO

23 days ago - By: Benzinga - Mentions: OMER VSTM MLSS CDTX ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

24 days ago - By: The Motley Fool

SeaStar Medical (ICU) Q3 2025 Earnings Transcript

24 days ago - By: SeaStar Medical

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

25 days ago - By: Benzinga

A Glimpse of SeaStar Medical Holding's Earnings Potential

a month ago - By: SeaStar Medical

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

2 months ago - By: SeaStar Medical

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

2 months ago - By: Stocktwits

SeaStar Medical Stock Jumps On Safety Board Backing For Kidney Trial; Retail Eyes Another Run Despite After-Hours Plunge

2 months ago - By: SeaStar Medical

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

3 months ago - By: SeaStar Medical

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

3 months ago - By: SeaStar Medical

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

3 months ago - By: SeaStar Medical

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

4 months ago - By: SeaStar Medical

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

4 months ago - By: SeaStar Medical

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

4 months ago - By: SeaStar Medical

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

4 months ago - By: SeaStar Medical

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

5 months ago - By: SeaStar Medical

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

5 months ago - By: SeaStar Medical

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

5 months ago - By: SeaStar Medical

SEASTAR MEDICAL HOLDING CORP (ICU) Stock News

ICU Latest News, Press Relases and Analysis

Get insights into the top gainers and losers of Tuesday's after-hours session.

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

SeaStar Medical Announces Appointment of Michael Messinger as CFO

12 Health Care Stocks Moving In Friday's Pre-Market Session

SeaStar Medical (ICU) Q3 2025 Earnings Transcript

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

A Glimpse of SeaStar Medical Holding's Earnings Potential

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical Stock Jumps On Safety Board Backing For Kidney Trial; Retail Eyes Another Run Despite After-Hours Plunge

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules